drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Engineered autologous T cells expressing a chimeric antigen receptor targeting B7-H3 (CD276), infused intravenously after lymphodepletion to mediate antigen-directed T-cell activation and cytotoxic killing of tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that recognizes B7-H3 (CD276) on tumor cells. CAR engagement triggers CD3ΞΆ/co-stimulatory signaling to activate, expand, and induce cytokine release and perforin/granzyme-mediated cytotoxic killing of target cells in an MHC-independent manner.
drug_name
Autologous B7-H3 CAR T cells (B7-H3CART)
nct_id_drug_ref
NCT06500819